OGN Stock Analysis: Buy, Sell, or Hold?
OGN - Organon & Co.
$8.54
-0.06 (-0.70%)
▼
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 12, 2026
12d
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called OGN this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OGN is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OGN is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.17
Based on 3.5% avg growth
INTRINSIC VALUE TODAY
$5.70
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $8.54, which is considered fair relative to its 30-day fair value range of $7.34 to $9.12. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.2) compared to its historical average (2.0). At these levels, the market is pricing in 3.5% annual earnings growth.
Technical Outlook: Technically, OGN is in a downtrend. Immediate support is located at $8.24, while resistance sits at $9.94.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OGN is in a downtrend. Immediate support is located at $8.24, while resistance sits at $9.94.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$7.34 -
$9.12
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.0%
Protect Your Profits
Holding OGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($9.36)
- BULLISH: Expecting earnings turnaround to 3.5% growth with 1.3% revenue growth
- WARNING: Recommendation downgraded due to -12.5% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$7.34 -
$9.12
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$8.24
Resistance Level
$9.94
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
2.22
Wall Street Target
$9.36
(+8.8%)
Revenue Growth (YoY)
1.3%
Earnings Growth (YoY)
-55.8%
Profit Margin
8.0%
Valuation Premium vs History
+3.5% premium
PE vs Historical
2.2 vs 2.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.5%
(market-implied from PE analysis)
1-Year Target
$8.90
(+4%)
2-Year Target
$9.21
(+7%)
3-Year Target
$9.53
(+11%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$8.58
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 2.9%)
$94.09
(+994%)
Base:
(SPY PE: 2.2, Growth: 2.9%)
$9.37
(+9%)
Bear:
(PE: 1.9, Growth: 2.9%)
$7.97
(-7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (5x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 4.71 | Current EPS (TTM): $1.91
Bull Case
$19.80
(+130%)
Analyst growth 100.0%, PE expands to 5.2
Base Case
$18.00
(+109%)
Market implied 100.0%, PE stable at 4.7
Bear Case
$6.12
(-29%)
Severe decline -20.0%, PE contracts to 4.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 5:38 PM ET
Data refreshes hourly during market hours. Next update: 6:38 PM
Data refreshes hourly during market hours. Next update: 6:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
